Skip to content
Select your cancer type
▼
  • ESCC
  • GC/GEJC
  • NSCLC
Indication:
▼
  • 1 L ESCC
  • 1 L GC/GEJC
  • 2 L ESCC
  • Non-Squamous NSCLC
  • Squamous NSCLC

Language

This site is inteded for health care proffesional.

Proven to extend mPFS in patients with advanced and metastatic Squamous NSCLC

Key Efficacy Outcome: mPFS

  Etapidi demonstrated clinical benefit regardless of PD-L1 expression. 

Progression-free survival by independent review committee:
all in the ITT analysis set; final analysis data cut-off.

by subgroup for etapidi + chemotheraphy(PC) vs chemoteraphy only

by subgroup for etapidi + chemotheraphy (nPC) vs chemoteraphy only